Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

scholar_rock_heather_faulds_headshot_bizwire

Scholar Rock prise Regulatory Affairs director away from Biogen

September 18, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Scholar Rock, biotech, drugs, pharma, pharmaceutical

Scholar Rock has announced that it has moved to appoint Heather Faulds as Vice President of Regulatory Affairs. Faulds joins …
Appointment
novartis_window

Novartis’ Xolair shows strong retreatment efficacy at Phase 3 in chronic spontaneous urticaria

September 18, 2017 Research and Development, Sales and Marketing Novartis, Xolair, chronic spontaneous urticarial, pharma, pharmaceutical

Novartis has released new data demonstrating the efficacy of Xolair (omalizumab) in the treatment of chronic spontaneous urticaria (CSU), a …
News
computer_and_doctor

Standing together: Supercharging the clinical trial in Europe

September 18, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, biotech, clinical trials, drugs, pharma, pharmaceutical

The European Medicines Agency is on the cusp of rolling out one of the most ground-breaking digital platforms for facilitating …
Feature
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

September 15, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cosentyx, Eli Lilly, Martin Skreli, Teva, pharma, top ten

This week has been a particularly eventful one for the industry: among our top stories, Martin Shkreli finally heads to …
News

Pfizer receives prostate cancer drug boost with trial results

September 15, 2017 Medical Communications, Research and Development Astellas, Pfizer, Xtandi, biotech, drugs, pharma, pharmaceutical

Pfizer, and its partner Astellas Pharma, received a major boost to its plans for prostate cancer treatment, Xtandi, by announcing …
News
sandoz

Sandoz psoriasis biosimilar tops reference product Humira in latest Phase 3 data

September 15, 2017 Medical Communications, Research and Development AbbVie, Humira, Novartis, Sandoz, adalimumab, biosimilar, biosimilars, pharma, pharmaceutical

Sandoz, the biologics and generics division of Novartis, has unveiled new Phase 3 data confirming the efficacy and safety profile …
News

Recipharm and Kancera collaborate to manufacture clinical trial supply

September 14, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Recipharm

Recipharm, a leading contract development and manufacturing organisation (CDMO) and Kancera, a development company focused on cancer therapy, have signed …
News
Press release
astrazeneca_logo_building

AstraZeneca’s Forxiga displays potential in type 1 diabetes

September 14, 2017 Research and Development AstraZeneca, Forxiga, biotech, drugs, farxiga, pharma, pharmaceutical

Forxiga is AstraZeneca’s treatment for those living with type 2 diabetes but the results from a new trial have found …
News
data

GDPR and Human Data Samples: Being ‘somewhat prepared’ is not enough

September 14, 2017 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GDPR, biotech, data, drugs, pharma, pharmaceutical

Thomas Hirse, Partner, and Paetrick Sakowski, Associate, CMS, discuss what pharmaceutical companies need to be aware of ahead of the …
Feature

Novo’s Xultophy beats basal insulin in cutting cardiovascular risk

September 14, 2017 Research and Development Novo Nordisk, Xultophy, diabetes, pharma, pharmaceutical, type 2 diabetes

Novo Nordisk has unveiled new data on its diabetes treatment Xultophy (insulin degludec/liraglutide) which supports its efficacy in reducing risk …
News
shutterstock_159488225

Amicus pulls plug on rare skin disease drug after Phase 3 failure

September 14, 2017 Research and Development Amicus, epidermolysis bullosa, pharma, pharmaceutical, trial failure

New Jersey-based biotech firm Amicus Therapeutics has been forced to terminate its development of its candidate for treating rare skin …
News
antibiotic_sensitvity_and_resistance

UK collaboration presents promising data in the fight against antibiotic resistance

September 13, 2017 Research and Development Auspherix, antibiotic resistance, domainex, pharma

The collaborative efforts of Domainex and Auspherix have made new progress in the development of a solution to the growing …
News
sanofi_regeneron

Sanofi/Regeneron new asthma data bolstered by potential indications

September 13, 2017 Research and Development Dupixent, Regeneron, Sanofi, biotech, drugs, pharma, pharmaceutical

Sanofi and Regeneron’s Dupixent is predicted to grow to be one of the largest selling drugs in the industry but …
News

Novartis’ Cosentyx proves long-term efficacy in psoriasis skin clearance

September 13, 2017 Research and Development Cosentyx, Novartis, pharma, pharmaceutical, psoriasis

At the European Academy of Dermatology and Venereology Congress in Geneva, Switzerland, Novartis unveiled new Phase 3 data for Cosentyx …
News
23andme

23andMe raises $250m in financing, research points towards its future

September 13, 2017 Research and Development, Sales and Marketing 23andME, biotech, drugs, pharma, pharmaceutical

23andMe made two announcements on the same day that point towards the future of its business: it revealed it had …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026